Clinical trials: Aripiprazole, completed
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418352
- Testing
- Aripiprazole
- Where
- 35 sites in United States, Bulgaria and 3 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alcohol Dependence
Aripiprazole Effects on Alcohol Drinking and Craving
The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving and drinking compared to placebo depending on participant's baseline level of impulsivity.
- Trial name
- NCT01292057
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Medical University of South Carolina
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Weight Gain, Autism Spectrum Disorder
Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
This study aims to compare two FDA approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders.
- Conditions
- Weight Gain, Autism Spectrum Disorder, Medication Side Effect
- Trial name
- NCT04903353
- Testing
- Comparison of Risperidone and Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia
Switching Medication to Treat Schizophrenia
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
- Trial name
- NCT00044655
- Testing
- Risperidone, Olanzapine, Ziprasidone
- Volunteers
- 219 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Asperger's Disorder, Pervasive Developmental Disorder
A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.
The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment for individuals with Asperger's Disorder and Pervasive Developmental Disorder.
- Trial name
- NCT00198055
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Indiana University
Alcohol Dependence
Aripiprazole Effects on Alcohol Reactivity and Consumption
The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer) is effective in reducing of alcohol craving compared to placebo.
- Trial name
- NCT00183235
- Testing
- aripiprazole (up to 15 mg/day) for 8 days
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical University of South Carolina
Schizophrenia
A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
The purpose of this study is to evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine monotherapy, in schizophrenic patients who are not optimally controlled on clozapine.
- Trial name
- NCT00300846
- Testing
- aripiprazole
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical…
- Trial name
- NCT00845026
- Testing
- LY2140023, aripiprazole, olanzapine
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 261 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
- Trial name
- NCT00080327
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 370 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia
- Trial name
- NCT00712686
- Testing
- Aripiprazole, Olanzapine
- Volunteers
- 690 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Conduct Disorder
Trial of Aripiprazole in the Treatment of CD in Adolescents
The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder.
- Trial name
- NCT00250705
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Schizophrenia
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on AOM treatment during an schizophrenia-related hospitalisation at least 6 months before data…
- Trial name
- PROSIGO (NCT03130478)
- Where
- 15 sites in Spain
- Volunteers
- 119 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Healthy
Aripiprazole and Lexapro Drug Interaction Study
The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of escitalopram in healthy subjects.
- Trial name
- NCT00361790
- Testing
- Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Adverse Drug Reaction
A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program
The INGenious trial will prospectively enroll a total of 6,000 patients, with 2,000 patients assigned to a pharmacogenetic testing arm and 4,000 to a control arm who will be followed, but not tested.
- Trial name
- INGenious (NCT02297126)
- Testing
- Pharmacogenetic Intervention Arm (pharmacogenetic testing)
- Where
- United States
- Volunteers
- 4,465 people
- Sponsor
- Indiana University
Autism Spectrum Disorder
Combination Treatment for Augmenting Language in Children With ASD
The study will consist of two main elements: the enrollment of 72 children aged 6-11 years with ASD and low language competency to receive a thrice-weekly one hour language intervention for 12 weeks; and, beginning at the same…
- Trial name
- PIII (NCT02574741)
- Testing
- Behavioral Therapy, Aripiprazole
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Bipolar 1 Disorder
Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder
This is a Post-Marketing Surveillance (PMS) of Abilify Maintena® Injections in accordance with Korean regulations on New Drug Re-examination (i.e.
- Trial name
- NCT03386851
- Where
- South Korea
- Volunteers
- 1,030 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Bipolar Disorder
Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
The purpose of this study is to look at the safety and effectiveness of aripiprazole (abilify) in children with bipolar disorder and to examine whether or not patients that respond to initial mood stabilization benefit from…
- Trial name
- NCT00194077
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia and Schizoaffective Disorder
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.
- Trial name
- NCT00292409
- Testing
- Aripiprazole
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autism, Asperger's Disorder
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
The aim of this study is to evaluate the efficacy, safety and tolerability of aripiprazole monotherapy in the treatment of children and adolescents suffering from Autism Spectrum Disorder (ASD) over a 12-week period.
- Conditions
- Autism, Asperger's Disorder, Pervasive Developmental Disorder
- Trial name
- NCT00308074
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cambridge Health Alliance